IRADIMED Future Growth
Future criteria checks 1/6
IRADIMED is forecast to grow earnings and revenue by 10.9% and 9.6% per annum respectively while EPS is expected to grow by 10.7% per annum.
Key information
10.9%
Earnings growth rate
10.70%
EPS growth rate
| Medical Equipment earnings growth | 16.2% |
| Revenue growth rate | 9.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 May 2026 |
Recent future growth updates
Recent updates
Narrative Update • Jun 04
IRMD: 2026 Guidance And Bullish Coverage Will Support Further Re Rating
Analysts have nudged their price target on IRADIMED slightly lower, from about $118.67 to $118.00. They are refining assumptions around discount rates, revenue growth, margins and future P/E expectations following recent bullish Street coverage.Narrative Update • Apr 30
IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating
Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.Narrative Update • Apr 12
IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating
Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.Narrative Update • Mar 26
IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating
Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.Narrative Update • Mar 11
IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing
Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.Narrative Update • Feb 25
IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple
Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.Narrative Update • Feb 10
IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support
Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.Narrative Update • Jan 27
IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook
Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.Narrative Update • Jan 12
IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced
Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.Narrative Update • Dec 14
IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks
Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.Narrative Update • Nov 29
IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks
IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.Narrative Update • Nov 15
IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum
Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.Narrative Update • Nov 01
IRMD: Index Addition and Strong Margins Will Support Measured Upside
Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.Analysis Article • Oct 09
Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Aug 13
IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up
Despite an already strong run, IRADIMED CORPORATION ( NASDAQ:IRMD ) shares have been powering on, with a gain of 27% in...Analysis Article • Aug 08
IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues
NasdaqGM:IRMD 1 Year Share Price vs Fair Value Explore IRADIMED's Fair Values from the Community and select yours The...Analysis Article • Jun 01
Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
New Narrative • Sep 24
Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins
Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.Analysis Article • Aug 08
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Despite announcing strong earnings, IRADIMED CORPORATION's ( NASDAQ:IRMD ) stock was sluggish. Our analysis uncovered...Analysis Article • Feb 23
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Feb 07
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Analysis Article • Nov 06
Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Analysis Article • Oct 13
Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Key Insights Using the 2 Stage Free Cash Flow to Equity, IRadimed fair value estimate is US$36.84 IRadimed's US$37.31...Analysis Article • Feb 05
At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 113 | 32 | 18 | 30 | 1 |
| 12/31/2027 | 101 | 28 | 22 | 28 | 2 |
| 12/31/2026 | 91 | 25 | 18 | 23 | 2 |
| 3/31/2026 | 86 | 24 | 24 | 29 | N/A |
| 12/31/2025 | 84 | 22 | 17 | 25 | N/A |
| 9/30/2025 | 81 | 21 | 14 | 25 | N/A |
| 6/30/2025 | 78 | 21 | 13 | 27 | N/A |
| 3/31/2025 | 75 | 20 | 14 | 26 | N/A |
| 12/31/2024 | 73 | 19 | 17 | 26 | N/A |
| 9/30/2024 | 71 | 19 | 17 | 24 | N/A |
| 6/30/2024 | 69 | 19 | 13 | 16 | N/A |
| 3/31/2024 | 68 | 18 | 11 | 13 | N/A |
| 12/31/2023 | 66 | 17 | 5 | 13 | N/A |
| 9/30/2023 | 63 | 16 | 5 | 13 | N/A |
| 6/30/2023 | 60 | 15 | 7 | 15 | N/A |
| 3/31/2023 | 56 | 14 | 5 | 13 | N/A |
| 12/31/2022 | 53 | 13 | 8 | 10 | N/A |
| 9/30/2022 | 50 | 13 | 9 | 10 | N/A |
| 6/30/2022 | 48 | 12 | 9 | 10 | N/A |
| 3/31/2022 | 45 | 10 | 11 | 12 | N/A |
| 12/31/2021 | 42 | 9 | 11 | 11 | N/A |
| 9/30/2021 | 38 | 6 | 10 | 10 | N/A |
| 6/30/2021 | 35 | 5 | 8 | 8 | N/A |
| 3/31/2021 | 32 | 1 | 5 | 6 | N/A |
| 12/31/2020 | 32 | 1 | 5 | 6 | N/A |
| 9/30/2020 | 34 | 4 | 7 | 7 | N/A |
| 6/30/2020 | 36 | 5 | 8 | 9 | N/A |
| 3/31/2020 | 39 | 10 | 10 | 11 | N/A |
| 12/31/2019 | 39 | 10 | N/A | 10 | N/A |
| 9/30/2019 | 36 | 8 | N/A | 10 | N/A |
| 6/30/2019 | 34 | 8 | N/A | 7 | N/A |
| 3/31/2019 | 32 | 7 | N/A | 6 | N/A |
| 12/31/2018 | 30 | 6 | N/A | 7 | N/A |
| 9/30/2018 | 29 | 5 | N/A | 5 | N/A |
| 6/30/2018 | 27 | 3 | N/A | 6 | N/A |
| 3/31/2018 | 25 | 2 | N/A | 5 | N/A |
| 12/31/2017 | 23 | 0 | N/A | 3 | N/A |
| 9/30/2017 | 22 | 1 | N/A | 4 | N/A |
| 6/30/2017 | 24 | 3 | N/A | 6 | N/A |
| 3/31/2017 | 29 | 5 | N/A | 7 | N/A |
| 12/31/2016 | 32 | 7 | N/A | 9 | N/A |
| 9/30/2016 | 35 | 8 | N/A | 10 | N/A |
| 6/30/2016 | 35 | 9 | N/A | 9 | N/A |
| 3/31/2016 | 33 | 8 | N/A | 9 | N/A |
| 12/31/2015 | 31 | 8 | N/A | 8 | N/A |
| 9/30/2015 | 26 | 5 | N/A | 4 | N/A |
| 6/30/2015 | 22 | 4 | N/A | 3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IRMD's forecast earnings growth (10.9% per year) is above the savings rate (3.5%).
Earnings vs Market: IRMD's earnings (10.9% per year) are forecast to grow slower than the US market (17.9% per year).
High Growth Earnings: IRMD's earnings are forecast to grow, but not significantly.
Revenue vs Market: IRMD's revenue (9.6% per year) is forecast to grow slower than the US market (12.5% per year).
High Growth Revenue: IRMD's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IRMD's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/11 06:44 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IRADIMED CORPORATION is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lawrence Solow | CJS Securities, Inc. |
| Ilya Zubkov | Freedom Broker |
| Frank Takkinen | Lake Street Capital Markets, LLC |